- Home
- RCKT vs FDMT Comparison
RCKT vs FDMT Comparison
Compare RCKT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | FDMT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 513.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RCKT | FDMT |
|---|---|---|
| Price | $4.87 | $8.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $29.65 | ★ $32.40 |
| AVG Volume (30 Days) | ★ 2.9M | 664.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | $97.68 | $161.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.19 | $2.24 |
| 52 Week High | $8.80 | $12.34 |
Technical Indicators
Market Signals| Indicator | RCKT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 58.97 | 45.06 |
| Support Level | $2.99 | $8.15 |
| Resistance Level | $5.34 | $8.80 |
| Average True Range (ATR) | 0.38 | 0.52 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 51.16 | 15.94 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.